Xanodyne newest pharm co. to cancel IPO
Xanodyne joins a growing number of biopharmaceutical and life science companies calling it quits on going public, at least for now. The Newport, Ky.-based firm withdrew its filing on Friday, citing poor market conditions — it had been waiting since November. Not that the company is really hurting. It’s raised about $232 million to date, and announced successful results in phase three trials of its lead drug candidate in August.
In the past, it has received… Continue Reading
Phenomix cancels IPO, finds new lab partner
Biopharmaceuticals company Phenomix withdrew its filing to go public yesterday and right away announced a $340-million collaboration deal with Forest Laboratories. The IPO, intended to raise $86.3 million, had been pending since January.
Forest will aid the San Diego-based firm in the development of its diabetes treatment, dutogliptin, which is currently in its third phase of clinical trials. The deal represented $75 million for the company up front, with potentially more to come as the drug… Continue Reading
Life-science briefing: Wednesday, April 2, 2008
TODAY’S HEADLINES:
ProGenTech takes in $21M for DNA purification systems (release)
Diabetes-drug maker Phenomix raises $18M while seeking IPO (Edgar)
Genome-tool maker BioTrove gets $23M in preparation for IPO (Edgar)
Sweden’s DermaGen pulls in more than €1M for dermatitis (release)
Digital health-record co. Medsphere receives $3M bridge (VentureWire)
CareAnyware, healthcare IT provider, takes $2M in debt (release)
Health B2B community CompareNetworks raises funding (release)
ActivBiotics assets sold for $3.5M (release)
ProGenTech takes in $21M for DNA purification systems – ProGenTech, an “East-West” tool and equipment maker,… Continue Reading
Life sciences briefing: Friday, Jan. 25, 2008
TODAY’S HEADLINES:
Health-info site HealthCentral Network pulls in $50M (paidContent)
BrightHeart Vet corrals $29M to acquire animal hospitals (release)
AviaraDx raises $8M for cancer diagnostics (peHUB)
Valor Medical aims for $15M for brain-aneurysm treatment (VentureWire)
IPC, inpatient-care provider, raises as much as $56M in IPO (IPO Home)
Phenomix, diabetes and hepatitis drug maker, files for $86M IPO (Edgar)
TVM Capital promotes Keiarasch “Kia” Parssanedjad to principal in life sciences (release)
BrightHeart Vet corrals $29M to acquire animal hospitals — BrightHeart Veterinary Centers, an… Continue Reading